CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CANCER-ID focuses on validating blood-based biomarkers like circulating tumor cells and DNA to enhance personalized cancer treatment. The project aims to develop standardized procedures for assessing these biomarkers, particularly when traditional biopsies are not feasible, ensuring better monitoring of treatment respo…
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients.
This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the associated risk of adverse events when taking a biopsy is high.
Furthermore, a longitudinal follow-up o…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Hamburg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Enschede
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Manchester
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Villejuif
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
